A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

NCT02773030 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

466

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: CC-220
DRUG: Dexamethasone
DRUG: Daratumumab
DRUG: Bortezomib
DRUG: Carfilzomib
DRUG: Daratumumab - 16mg/kg
DRUG: Bortezomib (BTZ)
DRUG: Daratumumab- 1800mg

Sponsor

Celgene